ArticlePakistan journal of medical sciences2026
Impact of
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Clopidogrel is essential to prevent cardiovascular events in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Despite adherence to clopidogrel, a significant number of cardiovascular events (CVEs) occur in patients after angioplasty. In this study, we sought to determine the association of CVEs with genetic polymorphisms in CYP2C19*2 (rs4244285) that affect metabolic activation of clopidogrel. Methodology: A prospective cohort study (n=204) was conducted from August 2022 to March 2023 at Khyber Medical University and Kuwait Teaching Hospital in Peshawar, Pakistan. STEMI patients (age 30-75 years, all genders) undergoing PCI were included and followed for 12 months. Genotyping of CYP2C19*2 (rs4244285) was performed by TaqMan assay. CVEs (mortality, stent thrombosis, recurrent MI, ischemic events and stroke) were compared between wild-type and variant genotypes. Statistical analysis used Fisher's exact test to compare CVEs between wild and mutant group, while binary logistic regression examined the relationship between CVEs and risk factors (SPSS v22). Results: The CYP2C19*2 (rs4244285) GA and AA genotypes were significantly associated with cardiovascular events (CVEs) (p < 0.003), whereas the wild-type GG genotype showed no significant correlation. During the 12-month follow-up after PCI, CVEs included: mortality (n = 10; GG = 2, GA+AA = 8), stent thrombosis (n = 5; GG = 0, GA+AA = 5), recurrent myocardial infarction (n = 9; GG = 1, GA+AA = 8), ischemia-related hospitalizations (n = 17; GG = 1, GA+AA = 16), and cerebrovascular accidents (n = 3; GG = 0, GA+AA = 3). Conclusion: Individuals carrying one or two non-functional CYP2C19*2 (rs4244285) alleles - GA and AA genotypes classified as intermediate and poor metabolizers, respectively- - showed a significant association with CVEs. Conversely, subjects with GG genotypes (normal metabolizers) had a significantly lower incidence of CVEs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.